Clinical and pharmaceutical features of using phytoneering medicines in the nefrological profile patients
Keywords:pathology of the urinary system, treatment, metaphylaxis, the drug “Canephron® N”, multivector pharmacodynamics, evidence-based medicine and pharmacy
According to the WHO the pathology of the urinary system affects the population of different ages and averages 10 % of the total population in the world. Today, in the domestic healthcare system there are about 500 thousand patients with chronic kidney disease, which is one of the most socially significant pathologies. The increase in the prevalence of urinary system diseases is primarily associated with a significant prevalence of diabetes mellitus, arterial hypertension and obesity, environmental degradation and uncontrolled drug use. Pathological changes in the kidneys also cause malnutrition, bad habits. The impaired renal function and other organs of the urinary system signal the body with many different symptoms, which are often disguised as symptoms of other diseases. That is why a person who first encounters manifestations of nephro- or uropathology does not always give them a serious meaning and begins to apply various treatment methods under his/her own responsibility, as opposed to responsible self-medication. The danger of this situation is that turning to the pharmacy a visitor focuses on the symptom that worries him/her most (most often it is pain in the lower back, lower abdomen, fever), and does not attach importance to other indicator symptoms of pathology. As part of pharmaceutical care the primary task of a pharmacist is to correctly assess the state of the pharmacy visitor taking into account both the nature and totality of his/her complaints, and the timely detection of “alarm” manifestations of urinary system diseases.
Nephro- and urology today is a branch of practical medicine, in which the use of herbal medicines is substantiated from the point of view of clinical pharmacology. And, if in acute forms of diseases their use is auxiliary, then in chronic diseases their role significantly increases. When carrying out metaphylaxis (anti-relapse treatment) for urinary tract infections and, especially, nephrolithiasis, herbal medicines are indispensable today. When choosing a drug for metaphylaxis of nephro- and uropathology a responsible professional in medicine and pharmacy will be guided by the data of evidence-based medicine as the highest determining category in the process of the rational pharmacotherapy, and a competent consumer in the framework of responsible self-medication should choose a drug with the greatest degree of trust (the brand recognition is determined, among other things, by consistently high quality). Thus, for the prevention and treatment of urinary system diseases the drug “Canephron® N” with the multivector pharmacodynamics, namely the diuretic, antispasmodic, anti-inflammatory, antibacterial, nephroprotective and antiplatelet action, has a significant evidence base.
Conclusions. The drug “Canephron® N” is an alternative choice for the treatment and prevention of patients with urinary tract diseases.
Pyroh, L. A., Ivanova, D. D. (2014). Nefrolohiia : natsionalnyi pidruchnyk. Donetsk : Vydavets Zaslavskyi, 292.
Chernykh, V. P., Zupantc, I. A., Kupnovitckaia, I. G. (Eds.). (2015). Klinicheskaia farmatciia : bazovyi ucheb. dlia studentov vysshikh farmatc. ucheb. za-vedeniia (farmatc. fak.) IV urovnia akkreditatcii. Kharkov: NFaU : Zolotye stranitcy, 1056.
Zupanets, I. A., Popov, S. B., Rudyk, Yu. S. (Eds.). (2018). Symptomy ta syndromy v praktychnii farmatsii. Pryntsypy terapii : navch. posib. dlia studentiv farmats. f-tiv vyshch. med. (farmats.) navch. zakl. osvity. Kharkiv: Zoloti storinky, 116.
Zupanetc, I. A., Chernykh, V. P., Sakharova, T. S., Popov, Y. B. (2012). Klinicheskaia farmatciia (farmatcevticheskaia opeka): ucheb. dlia studentov vysshikh med. ucheb. zavedenii. Kharkov: NFaU: Zolotye stranitcy, 776.
Chernykh, V., Zupantc, I., Popov, S. (Eds.). (2018). Farmatsevtychna opika: praktychnyi posibnyk. Kyiv: Farmatsevt Praktyk, 224.
Cherepanova, E. V., Dzeranov, N. K. (2010). Metafilaktika mochekamennoi bolezni v ambulatornikh usloviiakh. Eksperimentalnaia i klinicheskaia urologiia, 3, 33–39.
Nasybulina, N. M. (2009). Fitoterapiia mochekamennoi bolezni. Meditcinskaia sestra, 1, 45–48.
Kovalenko, V. N. (2018). Kompendium 2018 – lekarstvennye preparaty. Kyiv: Morion, 2560.
Zupantc, I., Shebeko, S. K., Volosovets, O. P.(Eds.). (2019). Farmatsevtychna opika patsiientiv pry symptomatychnomu likuvanni zakhvoriuvan sechovydilnoi systemy: metodychni rekomendatsii. Kharkiv: Zoloti storinky, 40.
Amosov, A. V., Aliaev, Iu. G., Saenko, V. S. (2010). Rastitelnyi lekarstvennyi preparat Kanefron N v posleope-ratcionnoi metafilaktike mochekamennoi bolezni. Urologiia, 5, 65–72.
Ivanov, D., Abramov-Sommariva, D., Moritz, K., Eskötter, H., Kostinenko, T., Martynyuk, L. Kolesnik, N. & Naber, K. G. (2015). An open label, non-controlled, multicentre, interventional trial to investigate the safety and efficacy of Canephron® N in the management of uncomplicated urinary tract infections (uUTIs). Clinical Phytoscience, 1–7.
Dudar, I. A. (2009). «12-mesiachnoe sravnitelnoe issledovanie primeneniia preparata Kanefron®N v lechenii patcientov s infektciiami mochevydelitelnoi sistemy». Zdorove muzhchiny, 3.
Medved, V. (2015). Safety of Canephron® N for the treatment of urinary tract infections in the first trimester of pregnancy. Clinical Phytoscience, 1–11.
Naber, K. (2013). Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. Research and Reports in Urology, 39. https://doi.org/10.2147/rru.s39288
Tykhonov, O. I., Yarnykh, T. H., Zupanets, I.A. (Eds.). (2010). Biofarmatsiia: pidruch. dlia stud. farmats. vuziv i fak. Kharkiv: NFaU: Zoloti storinky, 240.
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).